FDAnews Drug Daily Bulletin

Targeted Drug Slows Thyroid Cancer

Aug. 16, 2012
A A
In a small, placebo-controlled study, vandetanib (Caprelsa), a kinase inhibitor, delayed progression of the most common type of thyroid cancer, French researchers reported.
MedPage Today